Doctors stage non-small cell lung cancer (NSCLC) according to how far it has progressed. Stages range from occult (or hidden) cancer to stage 4 cancer, in which multiple organs may be affected.

Under the SEER classification system, "distant disease" and "stage 4 cancer" are synonymous. The one drawback to the SEER approach is that stage 4a and 4b lung cancer ar ...

In patients with locally advanced non–small cell lung cancer (NSCLC), combining PET with invasive staging methods led ... The study had a small sample size and potential selection bias as ...

Life expectancy for people with metastatic or metastasized lung cancer is low. The 5-year survival rate for small cell lung cancer is 3%, and 8% for non-small cell lung cancer (NSCLC). 25-30% of ...

Emerging data suggest that SBRT may be comparable with surgery for definitive treatment of stage I NSCLC in certain patients. When is one approach preferred and in whom?

Eighty-five percent of diagnosed cases of lung cancer are non-small cell lung cancer (NSCLC). In this group, 5% of patients ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Treatment with CAN-2409, an off-the-shelf immunotherapy, elicited responses among patients with pretreated stage 3/4 non–small cell lung cancer.

Ablation is when small tumors are destroyed by extreme heat or cold. There are several treatment options for stage 2 NSCLC.

Pembrolizumab and concurrent CRT, followed by pembrolizumab consolidation, provided long-term tumor control in previously untreated, unresectable, stage III NSCLC.

Despite the high incidence of brain metastasis after resection of non-small cell lung cancer (NSCLC), the National Comprehensive Cancer Network guidelines do not recommend central nervous system (CNS) ...